Labcorp (LH) Stock Price, News & Analysis

Company Overview

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services. Labcorp also develops consumer-oriented testing solutions and supports healthcare providers with laboratory information and diagnostic insights intended to assist with disease detection, treatment decisions and patient care.

Through its drug development business, Labcorp provides contract research and laboratory services to pharmaceutical, biotechnology and medical device companies. These services include clinical trial support, central laboratory testing, companion diagnostic development and other services used in the development and commercialization of new therapies. The company serves customers in the United States and international markets.

Labcorp traces its history to the laboratory businesses that became Laboratory Corporation of America Holdings following a 1995 combination involving National Health Laboratories and Roche Biomedical Laboratories. The company adopted the Labcorp name in 2022. Adam Schechter has served as Labcorp’s president and chief executive officer since 2019.

Key Stats

• Today's Range: $314.62 to $320.62
• 50-Day Range: $271.97 to $339.38
• 52-Week Range: $244.52 to $341.80
• Volume: 297,976 shs
• Average Volume: 675,445 shs
• Market Capitalization: $25.37 billion
• P/E Ratio: 25.99
• Dividend Yield: 0.92%
• Price Target: $330.00
• Consensus Rating: Moderate Buy

Labcorp Stock Analysis - MarketRank™

Labcorp scored higher than 85% of companies evaluated by MarketBeat, and ranked 84th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Labcorp has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Labcorp is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Labcorp has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.53%

Earnings Growth

Earnings for Labcorp are expected to grow by 7.53% in the coming year, from $18.32 to $19.70 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Labcorp is 26.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Labcorp is 26.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.75.

Price to Earnings Growth Ratio

Labcorp has a PEG Ratio of 1.84. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Labcorp has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Labcorp has recently decreased by 7.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Labcorp has a dividend yield of 0.89%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Labcorp does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Labcorp is 23.82%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Labcorp will have a dividend payout ratio of 14.62% next year. This indicates that Labcorp will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.76

News Sentiment

Labcorp has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Labcorp this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for LH on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

6 people have added Labcorp to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Labcorp insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,826,593.00 in company stock.

Percentage Held by Insiders

0.84% of the stock of Labcorp is held by insiders.

Percentage Held by Institutions

95.94% of the stock of Labcorp is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Record date for 9/11 Dividend: 8/28/2026
• Ex-Dividend for 9/11 Dividend: 8/28/2026
• Today: 9/10/2026
• Investor Day 2026: 9/10/2026
• Dividend Payable: 9/11/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NYSE:LH
• Previous Symbol: NYSE:LH?
• CIK: 920148
• Web: www.labcorp.com
• Phone: (336) 229-1127
• Fax: 336-513-4510
• Employees: 71,000
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Labcorp: $330.00
• High Price Target: $360.00
• Low Price Target: $300.00
• Potential Upside/Downside: +3.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $12.09
• Trailing P/E Ratio: 26.31
• Forward P/E Ratio: 17.33
• P/E Growth: 1.84
• Net Income: $876.50 million
• Net Margins: 6.99%
• Pretax Margin: 8.60%
• Return on Equity: 16.74%
• Return on Assets: 7.81%

Debt

• Debt-to-Equity Ratio: 0.69
• Current Ratio: 1.80
• Quick Ratio: 1.53

Sales & Book Value

• Annual Sales: $13.95 billion
• Price / Sales: 1.85
• Cash Flow: $24.27 per share
• Price / Cash Flow: 13.08
• Book Value: $103.98 per share
• Price / Book: 3.05

Miscellaneous

• Outstanding Shares: 81,100,000
• Free Float: 80,419,000
• Market Cap: $25.75 billion
• Optionable: Optionable
• Beta: 0.88